The Munich-based firm cited weak global demand, high energy costs, and competitive disadvantages as key factors behind its €800 million loss, with plans to cut costs and reduce staff by 1,500 jobs to stabilize finances.
The Trump administration's decision to weaken exposure limits for the cancer-linked chemical has reignited a decades-long fight between industry and public health advocates over what counts as sound science.
